Boundless Bio holders elect directors, ratify KPMG

Boundless Bio, Inc. held its annual stockholder meeting on June 15, 2026, where two proposals were approved.

(High)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Boundless Bio, Inc. held its annual stockholder meeting on June 15, 2026, where two proposals were approved. Stockholders elected James Christensen, Ph.D. and Jennifer Lew as Class II directors to serve until the 2029 annual meeting and until their successors are elected and qualified.

Christensen received 9,287,096 votes for and 512,585 votes withheld, while Lew received 9,271,084 votes for and 528,597 votes withheld; each had 5,757,105 broker non-votes. Stockholders also ratified KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 15,376,973 votes for, 127,747 against and 52,066 abstentions.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Annual meeting date: June 15, 2026 Votes for James Christensen: 9,287,096 votes Votes for Jennifer Lew: 9,271,084 votes +5 more

8 metrics

Annual meeting date June 15, 2026 Date of Boundless Bio’s annual stockholder meeting

Votes for James Christensen 9,287,096 votes Director election at 2026 annual meeting

Votes for Jennifer Lew 9,271,084 votes Director election at 2026 annual meeting

Broker non-votes on director elections 5,757,105 votes Same broker non-vote count for each nominee

Votes for KPMG ratification 15,376,973 votes Ratification of independent auditor for 2026 fiscal year

Votes against KPMG ratification 127,747 votes Opposing votes on auditor ratification proposal

Abstentions on KPMG ratification 52,066 votes Abstaining votes on auditor ratification proposal

Director term end 2029 annual meeting End of Class II directors’ term of office

Key Terms

broker non-votes, independent registered public accounting firm, Class II director

3 terms

broker non-votes financial

"Votes For | Votes Against | Abstentions | Broker Non-Votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

independent registered public accounting firm financial

"ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

Class II director financial

"Each of the director nominees was elected as a Class II director to hold office"

A class II director is a member of a company’s board who belongs to one of several staggered groups of directors, each group standing for election in different years. For investors, this matters because staggered terms slow wholesale board turnover—like rotating members of a neighborhood committee—making sudden changes in control or strategy harder and affecting how quickly shareholders can influence corporate direction.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Boundless Bio (BOLD) stockholders vote on at the 2026 annual meeting?

Stockholders voted on electing two Class II directors and ratifying KPMG LLP as auditor. Both proposals were approved, confirming the board slate and the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Who was elected to Boundless Bio (BOLD)’s board at the June 15, 2026 meeting?

James Christensen, Ph.D., and Jennifer Lew were elected as Class II directors. They will serve until Boundless Bio’s 2029 annual meeting of stockholders and continue until their respective successors are duly elected and qualified.

How many votes did Boundless Bio (BOLD) director nominees receive in 2026?

James Christensen, Ph.D., received 9,287,096 votes for and 512,585 withheld, while Jennifer Lew received 9,271,084 votes for and 528,597 withheld. Each nominee also had 5,757,105 broker non-votes recorded in the final tabulation.

Which auditing firm did Boundless Bio (BOLD) stockholders ratify for 2026?

Stockholders ratified KPMG LLP as Boundless Bio’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification received 15,376,973 votes for, 127,747 against, and 52,066 abstentions, with no broker non-votes reported.

When was Boundless Bio (BOLD)’s 2026 annual stockholder meeting held?

The annual meeting of stockholders was held on June 15, 2026. At this meeting, investors voted on electing two Class II directors and on ratifying KPMG LLP as the company’s independent registered public accounting firm for the 2026 fiscal year.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/17/2026 - 10:49 AM EDT

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): June 15, 2026

    

Boundless Bio, Inc.

(Exact Name of Registrant as Specified in Its Charter)


Delaware	001-41989	83-0751369
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

11099 North Torrey Pines Road, Suite 150
La Jolla, California		92037
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: (858) 766-9912

    

Alexandria Way, Suite 100

    

     San Diego, California 92121

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	BOLD	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

At the annual meeting of stockholders of Boundless Bio, Inc. (the Company) held on June 15, 2026 (the Meeting), two proposals were voted upon by the Company’s stockholders. The proposals are described in detail in the Company’s definitive proxy statement for the Meeting filed with the U.S. Securities and Exchange Commission on April 28, 2026. Below is a brief description of, and the final results of the votes for, each proposal.

Proposal 1: Each of the director nominees was elected as a Class II director to hold office until the Company’s 2029 annual meeting of stockholders, and until their respective successor is duly elected and qualified, by the votes set forth below.


Nominee	Votes For		Votes Withheld		Broker Non‑Votes
James Christensen, Ph.D.		9,287,096		512,585		5,757,105
Jennifer Lew		9,271,084		528,597		5,757,105

Proposal 2: The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 by the votes set forth below.


Votes For		Votes Against		Abstentions		Broker Non-Votes
	15,376,973		127,747		52,066		—

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			BOUNDLESS BIO, INC.

Date:	June 17, 2026	By:	/s/ Jessica Oien
			Name: Jessica Oien Title: Chief Legal Officer and Corporate Secretary

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document